摘要:
The present invention relates to an emulsion-type composition comprising a fattycontinuous phase, preferably of water-in-oil type, said composition comprising at least one polyglyceryl polyricinoleate,at least one polyol and at least one volatile linear alkane. It also relates to the use of such a composition for conferring on said composition improved comfort on application and/or improved stability.
摘要:
The invention relates to a pharmaceutical composition comprising factor VII encapsulated in micelles formed from block copolymer molecules containing (i) a hydrophilic polymer segment consisting of a polyalkylene glycol and (ii) a hydrophobic polymer segment consisting of a polyamino acid, with said polyamino acid comprising exclusively amino acid residues selected from the goup consisting of histidine, lysine, aspartic acid and glutamic acid residues, wherein a part of said amino acid residues is substituted with a hydrophobic group.
摘要:
L'invention vise des composés présentant une activité anti-parasitaire, notamment antipaludique, caractérisés en ce qu 'ils répondent à la formule générale (I)
Applications notamment comme composés à activité anti-parasitaire.
摘要:
The instant invention relates to the use of C-terminally truncated form of VDAC1 as a cell marker of apoptosis-resistance phenotype of hypoxic cancer cells.
wherein R1 and R2 independently represent a hydrogen atom, a (C 1 -C 4 )alkoxy group, a fluoro(C 1 -C 4 )alkoxy group, a hydroxyl group, a benzyloxy group, a di(C 1 -C 4 )alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a -NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C 1 -C 4 )alkyl group, a CONHR6 group, a -CONR7R8 group, a -SO 2 NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a -(CH 2 ) n NR7R8 group or a hydroxy(C 1 -C 4 )alkyl group; R6 represents a hydrogen atom, a -(CHR9) m (CH 2 ) n NR7R8 group or a (C 1 -C 6 )alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use as an agent for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.
摘要:
The invention relates to compounds of general formula (I): in which X1 is a hydrogen or halogen atom or a (C1-C6)-alkyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(C1-C3)-alkylene, (C1-C6)-fluoroalkyl, cyano, C(O)NR1R2, nitro, (C1-C6)-thioalkyl, -S(O)-(C1-C6)-alkyl, -S(O)2-(C1-C6)-alkyl, SO2NR1R2, aryl-(C1-C6)-alkylene, aryl or heteroaryl group, the aryl and the heteroaryl being optionally substituted; X2 is a hydrogen or halogen atom or a (C1-C6)-alkyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(C1-C3)-alkylene, (C1-C6)-fluoroalkyl, (C1-C6)-alkoxyl, (C3-C7)-cycloalkyl-(C1-C6)-alkylene-O-, (C1-C6)-fluoroalkoxyl, cyano, C(O)NR1R2, (C1-C6)-thioalkyl, -S(O)-(C1-C6)-alkyl, -S(O)2-(C1-C6)-alkyl, SO2NR1R2, aryl-(C1-C6)-alkylene, aryl or heteroaryl group, the aryl and the heteroaryl being optionally substituted; X3 and X4 are, independently of one another, a hydrogen or halogen atom or a (C1-C6)-alkyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(C1-C3)-alkylene, (C1-C6)-fluoroalkyl, (C1-C6)-alkoxyl, (C3-C7)-cycloalkyl-(C1-C6)-alkylene-O-, (C1-C6)-fluoroalkoxyl, cyano, C(O)NR1R2, nitro, NR1R2, (C1-C6)-thioalkyl, -S(O)-(C1-C6)-alkyl, -S(O)2-(C1-C6)-alkyl, SO2NR1R2, NR3COR4, NR3SO2R5, aryl-(C1-C6)-alkylene, aryl or heteroaryl group, the aryl and the heteroaryl being optionally substituted; Z1, Z2, Z3 and Z4 are, independently of one another, a nitrogen atom or a C(R6) group; n is equal to 0, 1, 2 or 3; Y is an optionally substituted aryl or heteroaryl; Ra and Rb are, independently of one another, a hydrogen atom or a (C1-C6)-alkyl, (C3-C7)-cycloalkyl, (C3-C7)-cycloalkyl-(C1-C3)-alkylene, (C1-C6)-fluoroalkyl, hydroxyl, (C1-C6)-alkoxyl, (C3-C7)-cycloalkyl-(C1-C6)-alkylene-O-, (C1-C6)-fluoroalkoxyl, aryl or heteroaryl group, wherein Ra and Rb may be optionally substituted; in the form of a base or an addition salt with an acid, and also in the form of a hydrate or of a solvate. Process for the preparation thereof and therapeutic use.
摘要:
The present invention relates to inhibitor of the activity of stearoyl-CoA-desaturase-1 (SCD-1) enzyme for use in the treatment of prostate cancer as well as to novel inhibitors of formula (IIa):
摘要:
The present invention provides a cosmetic kit for makeup and/or for care of keratinous material, comprising at least: ° a container containing at least one cosmetic composition comprising, in a physiologically acceptable medium, at least 16% by weight, preferably at least 18% by weight and more preferably at least 20% by weight of pigments and/or of film- forming polymers and/or of non-pulverulent thickening agents, relative to the total weight of said composition, said composition comprising at least one pigment; °an applicator device (8) for applying the composition, provided with an applicator member (10) including an application surface that is capable of turning about at least one axis (x) or center of rotation in response to being moved in engagement with the keratinous material.